James Richard Porter Sells 30,000 Shares of Nuvalent (NASDAQ:NUVL) Stock

Nuvalent, Inc. (NASDAQ:NUVL) CEO James Richard Porter sold 30,000 shares of the company’s stock in a transaction that occurred on Monday, April 6th. The stock was sold at an average price of $103.77, for a total value of $3,113,100.00. Following the completion of the sale, the chief executive officer directly owned 324,879 shares of the company’s stock, valued at approximately $33,712,693.83. This represents a 8.45% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Nuvalent Trading Up 2.7%

NUVL stock traded up $2.79 during midday trading on Wednesday, hitting $105.04. The company had a trading volume of 370,481 shares, compared to its average volume of 568,816. Nuvalent, Inc. has a 52 week low of $55.53 and a 52 week high of $113.01. The stock’s 50 day moving average price is $101.30 and its 200 day moving average price is $99.59. The stock has a market cap of $8.26 billion, a price-to-earnings ratio of -17.96 and a beta of 1.31.

Institutional Investors Weigh In On Nuvalent

A number of institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. grew its stake in shares of Nuvalent by 13.9% in the fourth quarter. Vanguard Group Inc. now owns 5,244,271 shares of the company’s stock worth $527,521,000 after acquiring an additional 639,264 shares during the last quarter. Wellington Management Group LLP grew its stake in shares of Nuvalent by 7.0% in the fourth quarter. Wellington Management Group LLP now owns 2,461,823 shares of the company’s stock worth $247,635,000 after acquiring an additional 160,958 shares during the last quarter. JPMorgan Chase & Co. grew its stake in shares of Nuvalent by 32.9% in the fourth quarter. JPMorgan Chase & Co. now owns 2,205,251 shares of the company’s stock worth $221,826,000 after acquiring an additional 545,542 shares during the last quarter. Price T Rowe Associates Inc. MD grew its stake in shares of Nuvalent by 18.6% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 2,146,938 shares of the company’s stock worth $215,962,000 after acquiring an additional 336,518 shares during the last quarter. Finally, RA Capital Management L.P. grew its stake in shares of Nuvalent by 50.8% in the fourth quarter. RA Capital Management L.P. now owns 1,880,057 shares of the company’s stock worth $189,115,000 after acquiring an additional 633,601 shares during the last quarter. 97.26% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

NUVL has been the topic of several recent research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Nuvalent in a research note on Thursday, January 22nd. Cantor Fitzgerald upped their price target on Nuvalent from $135.00 to $140.00 and gave the stock an “overweight” rating in a research note on Friday, February 27th. Wells Fargo & Company initiated coverage on Nuvalent in a research note on Monday, March 30th. They issued an “overweight” rating and a $116.00 price target on the stock. Wedbush reaffirmed an “outperform” rating and issued a $125.00 price target on shares of Nuvalent in a research note on Wednesday. Finally, JPMorgan Chase & Co. reduced their price target on Nuvalent from $147.00 to $145.00 and set an “overweight” rating on the stock in a research note on Friday, December 19th. Sixteen investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $137.25.

About Nuvalent

Nuvalent, Inc (NASDAQ:NUVL) is a clinical-stage precision oncology company focused on the discovery, development and commercialization of targeted therapies for patients with genetically defined cancers. Founded in 2019 and headquartered in San Diego, California, Nuvalent applies structure-guided drug design to develop small molecule inhibitors that address key oncogenic drivers. The company’s research platform integrates insights from cancer biology, medicinal chemistry and translational science to create therapies with differentiated selectivity and potency against validated targets.

Nuvalent’s lead pipeline candidates include NVL-520, a highly selective RET inhibitor designed to minimize off-target effects, and NVL-655, a potent covalent inhibitor targeting KRAS G12D mutations.